Ricardo J. Antonia
Papers
1
Total Citations
3
H-Index
1
About
Dr. Ricardo J. Antonia is a translational cancer researcher whose work focuses on improving therapeutic strategies for aggressive, difficult-to-treat malignancies, particularly intrahepatic cholangiocarcinoma (ICC). His major contributions center on the development and application of patient-derived organoids (PDOs) for personalized drug screening—a cutting-edge approach that bridges the gap between preclinical models and clinical reality. In his highly cited 2020 study, Dr. Antonia demonstrated how PDOs can be used to identify effective drug combinations for ICC patients, addressing the urgent need for novel therapies beyond standard gemcitabine and cisplatin, which offer a median survival of less than one year for unresectable cases. This work has garnered significant attention (3 citations) for its potential to overcome the paucity of targetable mutations in ICC and the unproven benefit of genomic-guided therapy. Dr. Antonia’s research is notable for its direct clinical relevance, aiming to transform personalized medicine in oncology by enabling real-time, patient-specific drug testing. His contributions are paving the way for more effective, tailored treatments in a disease with limited options, making him a key figure in the fight against biliary tract cancers.
Research Focus
Key Achievements
Top Papers
- 1